Posted by Michael Wonder on 16 Feb 2023
ICER releases draft evidence report on treatments for non-alcoholic steatohepatitis
16 February 2023 - The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of resmetirom (Madrigal Pharmaceuticals) and obeticholic acid (Ocaliva, Intercept Pharmaceuticals) for non-alcoholic steatohepatitis.
This preliminary draft marks the midpoint of ICER’s eight month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.
